Fiasp Insulin
Fiasp Insulin
Fiasp is a fast-acting insulin (insulin aspart) used to help control blood sugar levels in adults and children with diabetes. It starts working within minutes after injection and is typically taken at mealtime to manage post-meal blood glucose spikes.
Delivery
5-7 day
In Stock
Yes
Guaranteed
Source Canadian/UK PharmaciesFiasp is a modified insulin aspart formulation (100 U/mL) that includes nicotinamide (vitamin B₃) and L‑arginine, enabling insulin to enter the bloodstream about 5 minutes faster than standard rapid-acting insulins like NovoRapid/Novolog.
Indications & Dosing
-
Approved for adults, adolescents, and children aged 1+ with type 1 or type 2 diabetes.
-
Administered via subcutaneous injection, insulin pen, vial, or pump.
-
Dosed up to 2 minutes before a meal, or within 20 minutes after starting it for convenience.
Typically used alongside a basal or long-acting insulin as part of a basal-bolus regimen.
Indications & Dosing
-
Approved for adults, adolescents, and children aged 1+ with type 1 or type 2 diabetes.
-
Administered via subcutaneous injection, insulin pen, vial, or pump.
-
Dosed up to 2 minutes before a meal, or within 20 minutes after starting it for convenience.
-
Typically used alongside a basal or long-acting insulin as part of a basal-bolus regimen.
Pharmacokinetics & Pharmacodynamics
-
Onset occurs within 2.5 minutes; peak effect at ~1–3 hours; duration of action lasts 3–5 hours.
-
Studies show Fiasp rapidly lowers post-prandial glucose more effectively than NovoRapid
Benefits
-
Faster action offers tighter control of post-meal blood sugar and added flexibility—useful for those who forget pre-meal dosing.
-
Comparable HbA1c reductions and long-term glycemic control when compared to standard rapid-acting insulin.
In Summary
Fiasp is a modern, fast-acting mealtime insulin offering rapid onset and flexible dosing—ideal for tighter post-meal blood sugar control. It fits seamlessly into multiple delivery systems (pens, pump, vials), but its speed also carries an elevated risk of early hypoglycaemia, and some patients experience injection-site reactions or diminishing effects over time. Careful monitoring and individualized dosing are key to optimizing its use.
Let me know if you’d like a comparison with other fast-acting insulins like Lyumjev, pump compatibility specifics, or patient management tips!